Biogen Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Chris Viehbacher

İcra Kurulu Başkanı

US$24.2m

Toplam tazminat

CEO maaş yüzdesi	6.62%
CEO görev süresi	3yrs
CEO sahipliği	0.009%
Yönetim ortalama görev süresi	3.4yrs
Yönetim Kurulu ortalama görev süresi	4.4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Chris Viehbacher'un ücretlendirmesi Biogen'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2025	n/a	n/a	US$2b
Jun 30 2025	n/a	n/a	US$2b
Mar 31 2025	n/a	n/a	US$1b
Dec 31 2024	US$24m	US$2m	US$2b
Sep 30 2024	n/a	n/a	US$2b
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	US$4m	US$2m	US$1b
Sep 30 2023	n/a	n/a	US$1b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$3b
Dec 31 2022	US$30m	US$154k	US$3b

Tazminat ve Piyasa: Chris 'nin toplam tazminatı ($USD 24.17M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 13.47M ).

Tazminat ve Kazançlar: Chris şirketinin tazminatı %20'den fazla artarken, şirketin kazancı geçen yıl %20'den fazla düştü.

CEO

Chris Viehbacher (64 yo)

3yrs

Görev süresi

US$24,166,665

Tazminat

Mr. Christopher A. Viehbacher, also known as Chris, is Director of Innocoll Holdings plc from July 24, 2017. He serves as President and CEO at Biogen MA Inc. He joined the Innocoll Holdings plc on July 24,...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Viehbacher	President	3yrs	US$24.17m	0.0087% $ 2.0m
Nicole Murphy	Executive VP and Head of Pharmaceutical Operations & Technology	3.8yrs	US$5.74m	0.0097% $ 2.2m
Susan Alexander	Executive VP & Chief Legal Officer	19.8yrs	US$6.51m	0.038% $ 8.7m
Priya Singhal	Executive VP & Head of Development	5.8yrs	US$6.39m	0.0039% $ 889.4k
Robin Kramer	Executive VP & CFO	less than a year	Veri yok	0.0055% $ 1.2m
Sean Godbout	Chief Accounting Officer & Global Corporate Controller	less than a year	Veri yok	0.00034% $ 76.9k
Guy Hadari	Chief Information Officer	less than a year	Veri yok	Veri yok
Tim Power	Head of Investor Relations	less than a year	Veri yok	Veri yok
Adam Keeney	Executive VP & Head of Corporate Development	2.6yrs	Veri yok	0.0016% $ 368.9k
Ginger Gregory	Executive VP & Chief Human Resources Officer	8.3yrs	US$5.08m	0.012% $ 2.7m
Alisha Alaimo	President & Head of North America	8.3yrs	Veri yok	Veri yok
Anabella Villalobos	Head of Biotherapeutics & Medicinal Sciences	8.3yrs	Veri yok	Veri yok

3.4yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: BIIB 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Viehbacher	President	3yrs	US$24.17m	0.0087% $ 2.0m
Stephen A. Sherwin	Independent Director	15.7yrs	US$440.16k	0.0077% $ 1.7m
William Hawkins	Independent Director	6.4yrs	US$470.16k	0.0060% $ 1.4m
Caroline Dorsa	Independent Chair of the Board	15.8yrs	US$629.84k	0.019% $ 4.3m
Eric Rowinsky	Independent Director	15.7yrs	US$455.16k	0.015% $ 3.4m
Maria Freire	Independent Director	4.4yrs	US$443.77k	0.0046% $ 1.1m
Lloyd Minor	Director	1.1yrs	US$31.86k	0.0016% $ 366.6k
Monish Patolawala	Independent Director	1.8yrs	US$440.16k	0.0025% $ 572.6k
Menelas Nicolas Pangalos	Director	less than a year	Veri yok	Veri yok
Jesus Mantas	Independent Director	6.4yrs	US$469.55k	0.0066% $ 1.5m
Susan Langer	Independent Director	2.4yrs	US$425.77k	0.0035% $ 792.1k

4.4yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BIIB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.4 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/11/02 09:42
Gün Sonu Hisse Fiyatı	2025/10/31 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Biogen Inc. 62 Bu analistlerden 33, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
David Toung	Argus Research Company
Brian Skorney	Baird
James Birchenough	Barclays

Biogen Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Biogen Inc., Annual General Meeting, Jun 17, 2025

Independent Director recently sold US$1.3m worth of stock

Independent Director notifies of intention to sell stock

High number of new directors

Biogen Inc. Announces Appointment of Adam Feire as Head of Business Development and External Innovation

Biogen Inc. Appoints Daniel Quirk as Chief Medical Officer and Head of Medical Affairs

Recent updates

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025

Stoke Therapeutics, Inc. and Biogen Inc. Present New Data at the 54th Child Neurology Society Annual Meeting That Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

Biogen's Comeback: Why The Bulls Are Finally Winning Again

Eisai Co., Ltd. and Biogen Inc. Announce U.S. Availability of Leqemab-irmb Subcutaneous Injection Main Maintenance Dose for Treatment of Early Alzheimer's Disease

Investor sentiment improves as stock rises 16%

Biogen Inc. to Report Q3, 2025 Results on Oct 30, 2025

Eisai Co., Ltd. and Biogen Inc. Announces Therapeutic Goods Administration Approves for the Treatment of Alzheimer's Disease in Australia

Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Alcyone Therapeutics, Inc. for $85 million.

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

Stoke Therapeutics, Inc. and Biogen Inc. Present Data At the 36Th International Epilepsy Congress That Support the Potential for Zorevunersen to Be the First Disease-Modifying Medicine for Dravet Syndrome

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Stoke Therapeutics, Inc. and Biogen Inc. Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, A Potential Disease-Modifying Treatment for Dravet Syndrome

New minor risk - Earnings quality

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 12%

Eisai and Biogen Present Results on Lecanemab Subcutaneous Autoinjector At AAIC 2025

Biogen Inc. Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression

New minor risk - Insider selling

Stoke Therapeutics, Inc. and Biogen Inc. Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet Syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

Biogen Inc. to Report Q2, 2025 Results on Jul 31, 2025

Biogen Inc. Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

Biogen Inc. Announces New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Biogen Inc Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly

UCB and Biogen Inc. Announces Results from Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol in Systemic Lupus Erythematosus

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Biogen Inc., Annual General Meeting, Jun 17, 2025

Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?

Eisai Co., Ltd. and Biogen Inc. Announces Leqemab Marketing Authorization in the European Union

BioPharma Credit PLC Enters into Settlement Agreement with Biogen

Biogen: Balancing Risks And Opportunities

Independent Director recently sold US$1.3m worth of stock

Independent Director notifies of intention to sell stock

Eisai Co., Ltd. and Biogen Inc. Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative

Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma

Price target decreased by 11% to US$204

Biogen Inc. Provides Earnings Guidance for the Full Year 2025

Third quarter 2024 earnings released: EPS: US$2.67 (vs US$0.47 loss in 3Q 2023)

Consensus EPS estimates fall by 17%

Is Biogen (NASDAQ:BIIB) A Risky Investment?

High number of new directors

Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Eisai Co., Ltd. and Biogen Inc. Announces FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Biogen Inc. Announces Appointment of Adam Feire as Head of Business Development and External Innovation

Beaten Down Biogen Stock Looks Attractive At Current Levels

Market Cool On Biogen Inc.'s (NASDAQ:BIIB) Earnings

Eisai Co., Ltd. and Biogen Inc. Announces Approval of ''LEQEMBI" (Lecanemab) for the Treatment of Early Alzheimer's Disease in Mexico

Eisai Co., Ltd. and Biogen Inc. Announce "LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea

Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ

Eisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance Dosing

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter

Biogen Inc. Appoints Daniel Quirk as Chief Medical Officer and Head of Medical Affairs

Biogen Inc. Announces Chief Financial Officer Changes

Biogen Inc. to Report Q3, 2024 Results on Oct 30, 2024

Biogen Inc. Announces Elects Lloyd B. Minor and Sir Menelas (Mene) Pangalos as Directors, Effective October 1, 2024 and January 1, 2025, Respectively

Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Eisai Co., Ltd. and Biogen Inc. Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of Sage-324 (BIIB124) for the Treatment of Essential Tremor

Biogen Stock: Cheapish, But With Few Growth Prospects

Biogen Inc. (NasdaqGS:BIIB) completed the acquisition of Human Immunology Biosciences, Inc. from a group of sellers.

Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China

Biogen Inc. to Report Q2, 2024 Results on Aug 01, 2024

Biogen Inc. (NasdaqGS:BIIB) agreed to acquire Human Immunology Biosciences, Inc. from Alpha Wave Global, LP, Jeito Capital S.A., Viking Global Investors LP and others for approximately $1.8 billion.